Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) likes a challenge. As a specialist of difficult-to-treat central nervous system disorders, the company has been particularly successful with its multiple sclerosis treatment, H.P. Acthar Gel. In the massive biotechnology industry, Questcor is top-notch in terms of earnings per share growth and return on equity. For the upcoming year, analysts expect the company to grow earnings by 58% — almost double the rate expected for the rest of the industry! In the past two months, Wall Street analysts have upwardly revised their 2012 EPS estimates by 32%. This points to blowout growth in the next year, and I don’t want to miss a moment of it.
2012 Estimated Sales Growth: 54.5%
2012 Estimated Earnings Growth: 57.6%
Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) has been my one of my top five stocks ever since July, and it’s easy to see why. This stock is a heavyweight in terms of quarterly performance, delivering 64% sales growth and 158% earnings growth in the last quarter. Jazz’s flagship drug, Xyrem, is the only narcolepsy treatment approved by the World Anti-Doping Agency. For a disorder that affects as many as 200,000 Americans, that is significant. But Jazz is done with being a one-trick pony. The company is in the process of acquiring Azur Pharma Ltd., which will add 10 drugs to its roster in the U.S. And as the company moves its headquarters to Dublin, Jazz can take advantage of Ireland’s competitive tax rate. I can’t wait for the first quarter of 2012, when the deal is expected to close.
2012 Estimated Sales Growth: 70.4%
2012 Estimated Earnings Growth: -0.3%
Hansen Natural Corp. (NASDAQ:HANS) is a stock that we can get energized about — after all, it is the company behind the wildly successful Monster Energy drink line. Since August, it has been one of my top five stock picks for every single month (including this one). That is because there is a lot going for this stock. First, there has been talk for some time now that Hansen is a prime acquisition target by a larger beverage maker like Coca-Cola (NYSE:KO) or PepsiCo (NYSE:PEP). Also, the company has been aggressively expanding its Monster line in emerging markets like South America, Central and Eastern Europe, as well as Asia. And the company has been posting such great sales and earnings growth that Hansen is flush with cash. Of course, it has been putting this cash to great use, namely authorizing a $250 million stock buyback program. This company is going places, so make sure you don’t get left behind.
2012 Estimated Sales Growth: 15.4%
2012 Estimated Earnings Growth: 19.7%
Majesco Entertainment Co. (NASDAQ:COOL) develops and markets video game products primarily for family-oriented mass-market consumers. The future of this industry is dependent on nimble companies moving at light-speed. And with tremendous new game offerings that are getting high praise from customers, that describes COOL to a “T.” Watch for big jumps in the stock each earnings season in 2012.
2012 Estimated Sales Growth: 11.9%
2012 Estimated Earnings Growth: 12.5%
Flotek Industries, Inc. (NYSE:FTK) is, hands down, one of my top five favorite stocks for the new year. Remember the gold rush that happened in the United States? Everyone and their brother headed west looking for gold, but the people that made the real money were the ones that stood by the side of the trail and sold the picks, shovels and pans the miners needed. FTK is a “picks and shovels” play in the modern oil gold rush. The company provides the chemicals that are essential for drilling, cementing and countless other operations in the oil fields. Looking ahead, management is pushing for significant improvements in its oilfield tool technologies and for new developments in its chemical products — a great sign for new business and sales.
2012 Estimated Sales Growth: 27%
2012 Estimated Earnings Growth: 1.5%